Arginase 1 Deficiency Foundation Files Petition Urging Aeglea Biotherapeutics to Reinstate Life-Saving Drug Following Abrupt Withdrawal to Clinical Trial Patients in the United States Seattle, Washington, April 21, 2023: The Arginase 1 Deficiency Foundation, a leading advocacy group for individuals and families impacted by the debilitating rare metabolic disease, has launched a petition demanding that [...]

Pegzilarginase Clinical Trial Update (January 2023) As Aeglea previously announced, we are in the process of concluding our ongoing pegzilarginase Phase 1 and Phase 3 clinical trials and transitioning those patients to a new study. All patients in our two pegzilarginase clinical trials received their last dose before the end of December, and final [...]

Aeglea BioTherapeutics Submits BLA to FDA for Pegzilarginase for the Treatment of Arginase 1 Deficiency SEE ORIGINAL STORY HERE BLA submission provides FDA with all pegzilarginase program data to review in detail; Aeglea looks forward to working collaboratively with the FDA on next steps in the review process If approved, pegzilarginase would be the [...]

REDACTED - FDA Family-Led Listening Session Report On June 10, 2021, a group of patients and families affected by Arginase 1 Deficiency (ARG1-D) participated in a one-hour virtual listening session with officials from the Food and Drug Administration (FDA). The session enabled those with ARG1-D and their caregivers to  share their experiences, perspectives, needs, goals [...]

We’re proud to partner with the Child Neurology Foundation to conduct a survey to understand caregivers’ experiences on their journey in child neurology. Results will be shared with advocates and health care providers, so they are better able serve families. Caregivers of children with neurologic conditions can complete the brief survey thru April 1st at: www.surveymonkey.com/r/2022CNFCaregiverAssessment

PEGZILARGINASE Trial Discussion. Amazing presentation with Dr. Diaz, Dr. Burton and our own Tanja Brandt discuss Arginase 1 Deficiency, the Phase 2 and Phase 3 trial. Tanja discusses the day to day care taking of an individual with Arg1D. Great information on Arginase Deficiency 1 and the future of treating with the enzyme. This link [...]

I am excited to share with you that today we announced our Phase 3 PEACE (Pegzilarginase Effect on Arginase 1 Deficiency Clinical Endpoints) study achieved its primary endpoint with a statistically significant reduction in plasma arginine levels. Pronounced and sustained plasma arginine reduction was accompanied by a positive trend in the Gross Motor Function Measure Part E (GMFM-E), a key clinical assessment of patient mobility. Based on these [...]